ArticleFrontiers in veterinary science2025
Evaluation of immune protection of a multi-antigenic DNA vaccine encoding TgROP6 and TgMIC12 against
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nasal Nanoparticle Vaccine Induces a Cross-Strain T-Cell Immunity AgainstPharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Eukaryotic plasmids encoding pVAX-ROP6 and pVAX-MIC12 were constructed, and mice were immunized with either single or combined formulations. Results and discussion: Vaccination elicited a robust Th1-biased immune response, characterized by elevated IgG2a/IgG1 ratios, enhanced cytotoxic T lymphocyte activity, increased CD4+ and CD8+ T cell populations, and elevated production of IFN-γ, IL-12, and IL-2. The dual vaccine demonstrated superior efficacy, significantly prolonging survival following lethal RH challenge (compared to uniform mortality in controls by day 6) and reducing PRU brain cyst burden by 56.6%, outperforming single-gene formulations. Although these results establish pVAX-ROP6/MIC12 as promising vaccine candidates, protection remained partial, highlighting the need for further optimization. Overall, this study underscores the potential of bivalent DNA vaccines to induce broad protective immunity against toxoplasmosis, supporting their continued development for clinical and veterinary use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.